Storia in 16 fonti

GSK offers 40pc premium in US$10.6b bid for cancer drug developer Nuvalent

Deal values cancer drug developer Nuvalent at US$124 (RM503) per shareThat is a 40 per cent premium to the US-listed firm’s close yesterdayGSK CEO Miels says deals expands lung...

Raccontata da

cnbc.com

lecho.be

handelsblatt.com

thehindubusinessline.com

valor.globo.com+4 altre

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

malaymail.comStai leggendo7 h fa

GSK offers 40pc premium in US$10.6b bid for cancer drug developer Nuvalent

Deal values cancer drug developer Nuvalent at US$124 (RM503) per shareThat is a 40 per cent premium to the US-listed firm’s close yesterdayGSK CEO Miels says deals expands lung...

originale

Timeline cronologica

martedì 9 giugno 2026·cnbc.com
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
martedì 9 giugno 2026·lecho.be
GSK en pourparlers pour racheter Nuvalent pour plus de 9 milliards de dollars
GSK serait en discussions avancées pour racheter la biotech Nuvalent pour 9 à 10 milliards de dollars, selon le Financial Times. L’opération, qui pourrait être conclue dès cette…

GSK offers 40pc premium in US$10.6b bid for cancer drug developer Nuvalent

Confronto fonti

GSK offers 40pc premium in US$10.6b bid for cancer drug developer Nuvalent

Timeline cronologica

GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT

GSK en pourparlers pour racheter Nuvalent pour plus de 9 milliards de dollars

GSK to buy US lung cancer drug specialist Nuvalent for £8bn

UK pharma giant GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent

$10. 6 billion deal: GSK to buy US cancer specialist Nuvalent

GSK buys US biopharma company Nuvalent for $10.6B

Nuvalent: GSK übernimmt Krebsspezialisten für 10,6 Milliarden Dollar

Nuvalent: GSK übernimmt Krebsspezialisten

GSK in talks to buy cancer biotech Nuvalent for more than $9 billion

GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal

GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B

GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B

GSK to buy US lung cancer drug specialist Nuvalent for £8bn

GSK rachète Nuvalent pour plus de 10 milliards de dollars

UK pharma giant GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

Gsk sotto pressione a Londra, pesa l'accordo per l'acquisto di Nuvalent

Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket - Applied Digital (NAS

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent

GSK compra Nuvalent por US$ 10,6 bilhões e amplia aposta em oncologia

GSK buys US biopharma company Nuvalent for $10.6B

GSK offers 40pc premium in US$10.6b bid for cancer drug developer Nuvalent

Dow Jones Top Company Headlines at 9 AM ET: GSK to Buy Nuvalent for $10.6 Billion in Oncology Push | J.M. ...

Pharmalittle: We're reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more

Nuvalent vola a Wall Street: titolo in rialzo di quasi il 40% dopo l’annuncio dell’acquisizione da 10,6 miliardi di dollari da parte di Gsk…